A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| TAE684 | NVP-TAE684 is a highly potent and selective small-molecule ALK inhibitor, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC(50) values between 2 and 10 nM. NVP-TAE684 treatment resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest. In vivo, NVP-TAE684 suppressed lymphomagenesis in two independent models of ALK-positive ALCL and induced regression of established Karpas-299 lymphomas. NVP-TAE684 also induced down-regulation of CD30 expression, suggesting that CD30 may be used as a biomarker of therapeutic NPM-ALK kinase activity inhibition. Synonyms: TAE 684, TAE684, TAE-684, NVP-TAE 684, NVP-TAE684, NVP-TAE-684. CAS No. 761439-42-3. Molecular formula: C30H40ClN7O3S. Mole weight: 614.2017. |  |
| TAE 684 | TAE 684. Group: Biochemicals. Alternative Names: NVP-TAE 684; NVT TAE-684; 5-Chloro-N2-[2-methoxy-4-[4- (4-methyl-1-piperazinyl) -1-piperidinyl]phenyl]-N4-[2-[ (1-methylethyl) sulfonyl]phenyl]-2, 4-pyrimidinediamine. Grades: Highly Purified. CAS No. 761439-42-3. Pack Sizes: 10mg. Molecular Formula: C30H40ClN7O3S, Molecular Weight: 614.2. US Biological Life Sciences. |  Worldwide |
| TAE buffer (50X) | 1lt Pack Size. Group: Biochemicals, Buffers. Formula: N/A. Prepack ID 12439469-1lt. See USA prepack pricing. |  |
| Tafamidis | Tafamidis is a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. It is a drug for the amelioration of transthyretin-related hereditary amyloidosis. It functions by kinetic stabilization of the correctly folded tetrameric form of the transthyretin (TTR) protein and binds selectively and with negative cooperativity to the two normally unoccupied thyroxine-binding sites of the tetramer, and kinetically stabilizes TTR. Synonyms: Fx-1006A; Vyndaqel. Grades: >98%. CAS No. 594839-88-0. Molecular formula: C14H7Cl2NO3. Mole weight: 308.12. | |
| Tafasitamab | Tafasitamab is a humanized FC-modified monoclonal antibody that binds to CD19, which is broadly expressed on the surface of B cells. Tafasitamab is indicated for the treatment of B cell malignancies, such as non-Hodgkin's lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL). Synonyms: XmAb5574; MOR00208; MOR208; Tafasitamab-cxix. CAS No. 1422527-84-1. | |
| Tafenoquine | Tafenoquine is an oral active and an 8-aminoquinoline antimalaria drug. It is being investigated as a potential treatment for malaria, as well as for malaria prevention.It is for treatment of the hypnozoite stages of Plasmodium vivax and Plasmodium ovale that are responsible for relapse of these malaria species even when the blood stages are successfully cleared. It targets leishmania respiratory complex III and induces apoptosis. It has a long half-life of approximately 14 days and is generally safe and well tolerated, thus therefore a single treatment may be sufficient to clear hypnozoites. It was manufactured by GlaxoSmithKline and in clinic phase 3 trials. Uses: Tafenoquine is being investigated as a potential treatment for malaria, as well as for malaria prevention.it is for treatment of the hypnozoite stages of plasmodium vivax and plasmodium ovale. Synonyms: 4-[5-[3-(Trifluoromethyl)phenoxy]-2, 6-dimethoxy-4-methyl-8-quinolinylamino]-1-pentanamine; 8-[(4-Amino-1-methylbutyl)amino]-2, 6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinoline; N4-(2, 6-diMethoxy-4-Methyl-5-(3-(trifluoroMethyl)phenoxy)quinolin-8-yl)pentane-1, 4-diamine; WR-238605; WR238605; Etaquine. Grades: >98%. CAS No. 106635-80-7. Molecular formula: C24H28F3N3O3. Mole weight: 463.50. | |
| Tafenoquine Succinate | Tafenoquine is a medication for the prevention and treatment of malaria. Synonyms: WR 238605; WR-238605; WR238605. CAS No. 106635-81-8. Molecular formula: C28H34F3N3O7. Mole weight: 581.6. | |
| Tafluprost | Tafluprost is a novel prostanoid analogue that activates Prostaglandin Receptor. It is used in the treatment of glaucoma and is the first prostanoid to be released in a preservative free-formula. Synonyms: AFP-168, AFP-168, AFP-168, MK-2452, MK2452, MK 2452, Taflotan; Zioptan; AFP-168; Saflutan; propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate. Grades: ≥ 98%. CAS No. 209860-87-7. Molecular formula: C25H34F2O5. Mole weight: 452.539. | |
| Tafluprost | Tafluprost. Group: Biochemicals. Alternative Names: (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-Difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-5-heptenoic Acid 1-Methylmethyl Ester; AFP 168; MK 2452; Taflotan; Tapros. Grades: Highly Purified. CAS No. 209860-87-7. Pack Sizes: 2.5mg. Molecular Formula: C25H34F2O5, Molecular Weight: 452.53. US Biological Life Sciences. | Worldwide |
| Tafluprost acid | Synonyms: (Z)-7-[(1R,2R,3R,5S)-2-((E)-3,3-Difluoro-4-phenoxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl]hept-5-enoic Acid; 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-Difluoro-4-phenoxy-1-butenyl]-3,5-dihydroxycyclopentyl]-5-Heptenoic Acid; AFP 172. Grades: > 95%. CAS No. 209860-88-8. Molecular formula: C22H28F2O5. Mole weight: 410.46. | |
| Tafluprost-d7 | Tafluprost-d7. Group: Biochemicals. Alternative Names: (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-Difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-5-heptenoic Acid 1-Methylmethyl Ester-d7; AFP 168-d7; MK 2452-d7; Taflotan-d7; Tapros-d7. Grades: Highly Purified. Pack Sizes: 1mg. Molecular Formula: C25H27D7F2O5, Molecular Weight: 459.57. US Biological Life Sciences. | Worldwide |
| Tafluprost ethyl amide | Synonyms: Taflpostamide; (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]-N-ethylhept-5-enamide. CAS No. 1185851-52-8. Molecular formula: C24H33F2NO4. Mole weight: 437.5. | |
| Tafluprost ethyl ester | Tafluprost ethyl ester is an analog of prostaglandin F2α (PGF2α), which has been approved for the treatment of glaucoma. Synonyms: AFP 175; Ethyl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate. Grades: ≥98%. CAS No. 209860-89-9. Molecular formula: C24H32F2O5. Mole weight: 438.5. | |
| Tafluprost Impurity 10 | Tafluprost Impurity 10. Uses: For analytical and research use. Group: Impurity standards. CAS No. 40665-68-7. Molecular Formula: C11H15O5P. Mole Weight: 258.21. Catalog: APB40665687. |  |
| Tafluprost Impurity 11 | Tafluprost Impurity 11. Uses: For analytical and research use. Group: Impurity standards. CAS No. 39746-00-4. Molecular Formula: C15H16O5. Mole Weight: 276.29. Catalog: APB39746004. | |
| Tafluprost Impurity 19 | Tafluprost Impurity 19. Uses: For analytical and research use. Group: Impurity standards. CAS No. 2587078-46-2. Molecular Formula: C25H35FO5. Mole Weight: 434.55. Catalog: APB2587078462. | |
| Tafluprost Impurity 22 | Tafluprost Impurity 22. Uses: For analytical and research use. Group: Impurity standards. CAS No. 2587078-47-3. Molecular Formula: C25H34F2O5. Mole Weight: 452.54. Catalog: APB2587078473. | |
| Tafluprost Impurity 7 | Tafluprost Impurity 7. Uses: For analytical and research use. Group: Impurity standards. CAS No. 733036-94-7. Molecular Formula: C25H35FO5. Mole Weight: 434.55. Catalog: APB733036947. | |
| Tafluprost Impurity 8 | Tafluprost Impurity 8. Uses: For analytical and research use. Group: Impurity standards. CAS No. 2278245-92-2. Molecular Formula: C27H41BrO5. Mole Weight: 525.52. Catalog: APB2278245922. | |
| Tafluprost Impurity 9 | Tafluprost Impurity 9. Uses: For analytical and research use. Group: Impurity standards. CAS No. 2099033-66-4. Molecular Formula: C27H41NO8. Mole Weight: 507.62. Catalog: APB2099033664. | |
| Tafluprost Impurity DCP-1 | Tafluprost Impurity DCP-1. Uses: For analytical and research use. Group: Impurity standards. CAS No. 209860-88-8. Molecular Formula: C22H28F2O5. Mole Weight: 410.46. Catalog: APB209860888. | |
| Tafluprost Impurity DCP-2 | Tafluprost Impurity DCP-2. Uses: For analytical and research use. Group: Impurity standards. CAS No. 1563176-58-8. Molecular Formula: C25H34F2O5. Mole Weight: 452.54. Catalog: APB1563176588. | |
| TAG-1 A2 (78-86) | | |
| TAG-2 (42-50) | | |
| Tagatose | Tagatose is a white, anhydrous crystalline solid. It is a carbohydrate, a ketohexose, an epimer of D-fructose inverted at C-4. It can exist in several tautomeric forms. Synonyms: D-lyxo-Hexulose; (3S, 4S, 5R)-2-(hydroxymethyl)oxane-2, 3, 4, 5- tetrol; Naturlose; D-tagatose; tagatosum; tagatoza. CAS No. 87-81-0. Product ID: PE-0495. Molecular formula: C6H12O6. Mole weight: 180.16. Category: Sweetening agent. Product Keywords: Pharmaceutical Excipients; Excipients for Solid Dosage Form; Tagatose; Sweeteners Excipients; Sweetening agent; C6H12O6; 87-81-0; 87-81-0. UNII: T7A20Y888Y. Chemical Name: (3S, 4S, 5R)-1, 3, 4, 5, 6-pentahydroxyhexan-2-one. Administration route: oral and rectal. Dosage Form: oral and rectal solutions. Stability and Storage Conditions: Tagatose is stable under pH conditions typically encountered in foods (pH > 3). It is a reducing sugar and undergoes the Maillard reaction. Tagatose is stable under typical storage conditions. It caramelizes at elevated temperature. Source and Preparation: Tagatose is obtained from D-galactose by isomerization under alkaline conditions in the presence of calcium. Applications: Tagatose is used as a sweetening agent in beverages, foods, and pharmaceutical applications. A 10% solution of tagatose is about 92% as sweet as a 10% sucrose solution.It is a low-calorie sugar with approximately 38% of the calories of sucrose per gram. It occurs naturally in low levels in milk pro |  |
| tagatose-6-phosphate kinase | This enzyme belongs to the family of transferases, specifically those transferring phosphorus-containing groups (phosphotransferases) with an alcohol group as acceptor. The systematic name of this enzyme class is ATP:D-tagatose-6-phosphate 1-phosphotransferase. This enzyme participates in galactose metabolism. Group: Enzymes. Enzyme Commission Number: EC 2.7.1.144. CAS No. 39434-00-9. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-2974; tagatose-6-phosphate kinase; EC 2.7.1.144; 39434-00-9. Cat No: EXWM-2974. |  |
| tagatose-bisphosphate aldolase | Enzyme activity is stimulated by certain divalent cations. It is involved in the tagatose 6-phosphate pathway of lactose catabolism in bacteria. Group: Enzymes. Synonyms: D-tagatose-1,6-bisphosphate triosephosphate lyase. Enzyme Commission Number: EC 4.1.2.40. CAS No. 39433-95-9. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-4876; tagatose-bisphosphate aldolase; EC 4.1.2.40; 39433-95-9; D-tagatose-1,6-bisphosphate triosephosphate lyase. Cat No: EXWM-4876. | |
| tagatose kinase | This enzyme belongs to the family of transferases, specifically those transferring phosphorus-containing groups (phosphotransferases) with an alcohol group as acceptor. This enzyme participates in galactose metabolism. Group: Enzymes. Enzyme Commission Number: EC 2.7.1.101. CAS No. 39434-00-9. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-2948; tagatose kinase; EC 2.7.1.101; 39434-00-9. Cat No: EXWM-2948. | |
| tagaturonate reductase | This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-altronate:NAD+ 3-oxidoreductase. Other names in common use include altronic oxidoreductase, altronate oxidoreductase, TagUAR, altronate dehydrogenase, and D-tagaturonate reductase. This enzyme participates in pentose and glucuronate interconversions. Group: Enzymes. Synonyms: altronic oxidoreductase; altronate oxidoreductase; TagUAR; altronate dehydrogenase; D-tagaturonate reductase. Enzyme Commission Number: EC 1.1.1.58. CAS No. 9028-45-9. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-0343; tagaturonate reductase; EC 1.1.1.58; 9028-45-9; altronic oxidoreductase; altronate oxidoreductase; TagUAR; altronate dehydrogenase; D-tagaturonate reductase. Cat No: EXWM-0343. | |
| Tagette Oil | Tagette Oil. CAS No. 8016-84-0. FEMA No. 3040. Kosher: Y. VIGON Item # 504279. Categories: Speciality Ingrdients Suppliers, Flavors, Fragrances, Perfumers, Aromatherapy, Essetial Oils. |  America & Internationally |
| TAI-1 | TAI-1 disrupts the binding of Nek2 to Hec1, which leads to degradation of Nek2 and chromosomal misalignment. Synonyms: TAI-1; TAI1; TAI 1. Grades: >98%. CAS No. 1334921-03-7. Molecular formula: C24H21N3O3S. Mole weight: 431.51. | |
| TAICATOXIN | Heterocyclic Organic Compound. Alternative Names: TCX;TAICATOXIN;taicatoxin from oxyuranus s. scutellatus (taipan snake) venom. CAS No. 112154-17-3. Catalog: ACM112154173. |  |
| TAIKh 211 (9CI) | Heterocyclic Organic Compound. CAS No. 113610-04-1. Catalog: ACM113610041. | |
| Taipehensin-B1 antimicrobial peptide precursor | Taipehensin-B1 antimicrobial peptide precursor is an antibacterial peptide isolated from Hylarana taipehensis. Synonyms: Thr-Met-Lys-Lys-Leu-Leu-Leu-Leu-Phe-Phe-Phe-Leu-Gly-Thr-Ile-Ser-Ser-Ser-Leu-Cys-Glu-Lys-Glu-Arg-Asp-Ala-Asp-Glu-Asp-Glu-Val-Asn-Arg-Gly-Glu-Ala. Grades: >98%. | |
| TAK-044 | Tak-044 has been found to be an endothelin receptor antagonist that was once studied against some sort of liver disorders and subarachnoid haemorrhage. Synonyms: TAK-044, TAK 044, TAK044; CHEMBL61425; AC1L3XH4; Cyclo(D-alpha-aspartyl-3-((4-phenylpiperazin-1-yl)carbonyl)-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl) disodium salt; AM017317. Grades: 98%. CAS No. 157380-72-8. Molecular formula: C45H51N9Na2O11S. Mole weight: 971.99. | |
| TAK-063 | TAK-063 is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK-063 is currently being evaluated in clinical trials for the treatment of schizophrenia. Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP phosphodiesterase highly expressed in medium spiny neurons (MSNs) in the striatum. TAK-063 represents a promising drug for the treatment of schizophrenia with potential for superior safety and tolerability profiles. Synonyms: TAK063, TAK 063, TAK-063, Balipodect. Grades: >98%. CAS No. 1238697-26-1. Molecular formula: C23H17FN6O2. Mole weight: 428.42. | |
| TAK-070 | TAK-070, under the IUPAC name 2-Naphthaleneethanamin?e, 6-([1,?1'-biphenyl]?-4-ylmethoxy)?-1,?2,?3,?4-tetrahydro-N,?N-dimethyl-, hydrochloride, hydrate (1:1:1)?, (2R)?-, a novel noncompetitive BACE1 inhibitor, ameliorated Aβ pathology and behavioral deficits in Tg2576. Phase 1. Synonyms: TAK-070; TAK 070; TAK070; 2-Naphthaleneethanamin?e, 6-([1,?1'-biphenyl]?-4-ylmethoxy)?-1,?2,?3,?4-tetrahydro-N,?N-dimethyl-, hydrochloride, hydrate (1:1:1)?, (2R)?-; 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, monohydrate, (2R)- (9CI); UNII-EAC604ZY07; 365276-12-6. CAS No. 365276-12-6. Molecular formula: C27H31NO.HCl.H2O. Mole weight: 440.02. | |
| TAK-071 | TAK-071 is a positive allosteric modulator of muscarinic acetylcholine receptor 1 (M1R). Uses: Muscarinic agonists. Synonyms: TAK-071; 1820812-16-5; UNII-59XC9G796Y; 59XC9G796Y; 4-Fluoro-2-((3S, 4S)-4-hydroxytetrahydro-2H-pyran-3-yl)-5-methyl-6-(4(1H-pyrazol-1-yl)benzyl)-2, 3-dihydro-1H-isoindol-1-one; L-Threo-pentitol, 1,5-anhydro-2,4-dideoxy-2-(4-fluoro-1,3-dihydro-5-methyl-1-oxo-6-((4-(1H-pyrazol-1-yl)phenyl)methyl)-2H-isoindol-2-yl)-; 4-fluoro-2-[(3S,4S)-4-hydroxyoxan-3-yl]-5-methyl-6-[(4-pyrazol-1-ylphenyl)methyl]-3H-isoindol-1-one; 6-(4-(1H-PYRAZOL-1-YL)BENZYL)-4-FLUORO-2-((3S,4S)-4-HYDROXYTETRAHYDRO-2H-PYRAN-3-YL)-5-METHYLISOINDOLIN-1-ONE; CHEMBL4594351; SCHEMBL17201222; GTPL12302; WFSARWQASFQZMG-VXKWHMMOSA-N; AKOS040739717; AC-31580; MS-27399; HY-122190; CS-0082523; D77973; 1,5-anhydro-2,4-dideoxy-2-(4-fluoro-5-methyl-1-oxo-6-(4-(1H-pyrazol-1-yl)benzyl)-1,3-dihydro-2H-isoindol-2-yl)-L-threo-pentitol; 4-fluoro-2-[(3s,4s)-4-hydroxytetrahydro-2h-pyran-3-yl]-5-methyl-6-[4-(1h-pyrazol-1-yl)benzyl]-2,3-dihydro-1h-isoindol-1-one. Grades: 98%. CAS No. 1820812-16-5. Molecular formula: C24H24FN3O3. Mole weight: 421.5. | |
| TAK 165 | TAK 165. Group: Biochemicals. Grades: Purified. CAS No. 366017-09-6. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| TAK 21d | TAK 21d. Group: Biochemicals. Grades: Purified. CAS No. 1143578-94-2. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| TAK 21d | TAK 21d is a potent and brain penetrating FAAH inhibitor (IC50 = 0.28 and 0.72 nM at rat and human FAAH, respectively). TAK 21d exhibits analgesic effects in vivo models of neuropathic and inflammatory pain. Synonyms: TAK-21d; TAK 21d; TAK21d; TAK-21-d; 4-[4-(3,4-Difluorophenyl)-2-pyrimidinyl]-N-3-pyridazinyl-1-piperazinecarboxamide. Grades: ≥98% by HPLC. CAS No. 1143578-94-2. Molecular formula: C19H17F2N7O. Mole weight: 397.38. | |
| TAK-220 | TAK-220 is an orally bioavailable small-molecule CCR5 antagonist. Synonyms: TAK-220, TAK 220, TAK220; 1-acetyl-N-[3-[4-[(4-carbamoylphenyl)methyl]piperidin-1-yl]propyl]-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide. Grades: 99.95%. CAS No. 333994-00-6. Molecular formula: C31H41ClN4O3. Mole weight: 553.14. | |
| TAK-243 | TAK-243, a pyrazolopyrimidine derivative, has been found to be an Ubiquitin-protein ligase inhibitor and was just finished the Phase-I trial against solid tumors. Synonyms: TAK-243; TAK 243; TAK243; MLN7243; MLN-7243; MLN 7243; AOB87172; AOB-87172; AOB 87172. Grades: 98%. CAS No. 1450833-55-2. Molecular formula: C19H20F3N5O5S2. Mole weight: 519.51. | |
| TAK-243 | TAK-243 Inhibitor. Uses: Scientific use. Product Category: T16974. CAS No. 1450833-55-2. |  |
| TAK-259 HCl | This active molecular is a selective α1D Adrenergic Receptor antagonist. ( Ki value of 1.1 nM, 200 fold selective over α1A and 800 fold selective over α1B). TAK-259 exhibited a larger MRTpo value and potent antiurinary frequency efficacy. In Jul 2011, Phase-I clinical trials in Overactive bladder in Japan is on going. In Feb 2013, Phase-I for Overactive bladder in Japan was discontinued. Uses: Overactive bladder. Synonyms: TAK-259, TAK259, TAK259; 5-chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide hydrochloride,1192348-73-4 (free base). Grades: 98%. CAS No. 1192347-42-4. Molecular formula: C14H14Cl3N3O3S. Mole weight: 410.69. | |
| TAK-285 | TAK-285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK-285 is currently being developed by Takeda. TAK-285 was found to be well tolerate in Phase I trials. Absorption of TAK-285 was rapid after oral dosing, and plasma exposure at steady-state increased in a dose-proportional fashion for doses ranging from 50 to 300?mg b.i.d. A partial response was observed for one patient with parotid cancer who received 300?mg b.i.d. The toxicity profile and PK properties of oral TAK-285 warrant further evaluation. Synonyms: TAK285; TAK 285. CAS No. 871026-44-7. Molecular formula: C26H25ClF3N5O3. Mole weight: 547.963. | |
| TAK-438 | TAK-438 Inhibitor. Uses: Scientific use. Product Category: T2404. CAS No. 1260141-27-2. | |
| TAK-441 | TAK-441 is a potent inhibitor of Hedgehog (Hh) signaling pathway, TAK-441 is also a novel pyrrolo[3,2-c]quinoline-4-one derivative, which chemical structure is shown as the following. TAK-441 showed activity to suppress transcription factor Gli1 mRNA expression in tumor-associated stromal tissue and inhibited tumor growth (treatment/control ratio, 3%) in a mouse medulloblastoma allograft model owing to the improved PK profile based on increased solubility. TAK-441 is currently in clinical trials for the treatment of advanced solid tumors. Synonyms: TAK441; TAK 441. CAS No. 1186231-83-3. Molecular formula: C28H31F3N4O6. Mole weight: 576.57. | |
| TAK-448 | TAK-448 is a KISS1R protein agonist as a oligopeptide analog of kisspeptin. In animal model, TAK-448 can stimulate LH/FSH release, whereas continuous sc exposure rapidly down-regulates the pituitary-gonadal axis, with rapid reduction of T levels in a dose-dependent manner. Phase II clinical trials for the treatment of Prostate cancer was discontinued. In Dec 2016, Takeda terminated a phase II trial in Hypogonadism (In adults, In the elderly) in USA because the study did not meet the primary endpoints. Uses: Hypogonadism;prostate cancer. Synonyms: MVT-602; Ac-D-Tyr-D-Trp-Asn-Thr-Phe-azaGly-Leu-Arg(Me)-Trp-NH2; RVT-602; RVT 602; TAK 448; RVT602; TAK448; N-acetyl-D-tyrosyl-(4R)-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl-2-azaglycyl-L-leucyl-N5-(imino(methylamino)methyl)-L-ornithyl-L-Tryptophanamide; Istaroxime; (2S,5S,8S,14S,17S,20S)-20-[({(2S,4R)-1-[(2R)-2-Acetamido-3-(4-hydroxyphenyl)propanoyl]-4-hydroxy-2-pyrrolidinyl}carbonyl)amino]-14-benzyl-17-(1-hydroxyethyl)-2-(1H-indol-3-ylmethyl)-8-isobutyl-5-[3-(N'-methylcarbamimidamido)propyl]-4,7,10,13,16,19-hexaoxo-3,6,9,11,12,15,18-heptaazadocosane-1,22-diamide. Grades: 98%. CAS No. 1234319-68-6. Molecular formula: C58H80N16O14. Mole weight: 1225.36. | |
| TAK-593 | TAK-593 is an oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. TAK-593 selectively binds to and inhibits VEGFR and PDGFR, which may result in the inhibition of angiogenesis and tumor cell proliferation. Check for active clinical trials or closed clinical trials using this agent. Synonyms: TAK593; TAK 593. Grades: >98%. CAS No. 1005780-62-0. Molecular formula: C23H23N7O3. Mole weight: 445.483. | |
| TAK-603 | TAK-603, a quinoline derivative, has been found to be an immunomodulator that was once studied in sorts of inflammatory diseases. Synonyms: TAK-603, TAK603, TAK 603; Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate; UNII-W6RZK26FCB; W6RZK26FCB; AC1L4BH6. Grades: 98%. CAS No. 158146-85-1. Molecular formula: C25H26N4O6. Mole weight: 478.51. | |
| TAK-632 | TAK-632 is a potent pan-RAF inhibitor with favorable in vitro activity (BRAF(V600E) IC50 value of 2.4 nM. Synonyms: TAK632, TAK 632, TAK-632. CAS No. 1228591-30-7. Molecular formula: C27H18F4N4O3S. Mole weight: 554.51. | |
| TAK-659 dihydrochloride | TAK-659 is a potent spleen tyrosine kinase (syk) inhibitor under the development of Takeda Oncology, with potential anti-inflammatory, immunomodulating, and antineoplastic activities. TAK-659 may inhibit the activity of syk, which abrogates downstream BCR (B-cell receptor) signaling and leads to an inhibition of B-cell activation, chemotaxis, adhesion and proliferation. Phase I/II for the treatment Acute myeloid leukaemia, phase I for the treatment of Breast cancer, Gastrointestinal cancer, Head and neck cancer, Lymphoma, Non-small cell lung cancer and Solid tumours was on-going. Uses: Acute myeloid leukaemia;breast cancer; gastrointestinal cancer; head and neck cancer; lymphoma; non-small cell lung cancer; solid tumours most recent events. Synonyms: 6-(((1R,2S)-2-aminocyclohexyl)amino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one dihydrochloride; TAK659; TAK-659; TAK 659; TAK-659 HCl; TAK659 dihydrochloride. Grades: 98%. CAS No. 1312691-41-0. Molecular formula: C17H23Cl2FN6O. Mole weight: 417.31. | |
| TAK-659 hydrochloride | TAK-659 hydrochloride is a hydrochloride salt of TAK-659 which is a potent spleen tyrosine kinase (syk) inhibitor (IC50 = 3.2 nM) under the development of Takeda Oncology, with potential anti-inflammatory, immunomodulating, and antineoplastic activities. Synonyms: TAK-659 hydrochloride; TAK 659 hydrochloride; TAK659 hydrochloride; 6-[[(1R,2S)-2-aminocyclohexyl]amino]-7-fluoro-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one;hydrochloride; TAK-659 HCl. CAS No. 1952251-28-3. Molecular formula: C17H22ClFN6O. Mole weight: 380.85. | |
| TAK-683 | TAK-683 is an investigational peptide derivative of metastin under the development of Millennium. It is a KISS1R protein agonist. Phase I development for prostate cancer was discontinued. Uses: Prostate cancer. Synonyms: TAK-683, TAK 683, TAK683; (S)-2-((R)-2-((R)-2-acetamido-3-(4-hydroxyphenyl)propanamido)-3-(1H-indol-3-yl)propanamido)-N1-((8S,11S,17S,20S,21R)-8-(((S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamoyl)-17-benzyl-21-hydroxy-3-imino-11-isobutyl-10,13,16,19-tetraoxo-2,4,9,12,14,15,18-heptaazadocosan-20-yl)succinamide. Grades: 98%. CAS No. 872719-49-8. Molecular formula: C64H83N17O13. Mole weight: 1298.47. | |
| TAK-700 | TAK-700 (Orteronel) is a potent and highly selective human 17,20-lyase inhibitor with IC50 of 38 nM, exhibits >1000-fold selectivity over other CYPs (e.g. 11-hydroxylase and CYP3A4). It completed two phase III clinical trials for metastatic, hormone-refractory prostate cancer but failed to extend overall survival rates, and development was voluntarily terminated as a result. Synonyms: TAK-700; TAK700; (S/R)-Orteronel; 6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide. Grades: >98%. CAS No. 426219-18-3. Molecular formula: C18H17N3O2. Mole weight: 307.35. | |
| TAK 715 | TAK 715. Group: Biochemicals. Grades: Purified. CAS No. 303162-79-0. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| TAK-715 | TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Synonyms: TAK715, TA 715, TAK715. Grades: 0.99. CAS No. 303162-79-0. Molecular formula: C24H21N3OS. Mole weight: 399.512. | |
| Tak-733 | Heterocyclic Organic Compound. Alternative Names: TAK-733;TAK-733/TAK733;(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione;(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dioneTAK 733. CAS No. 1035555-63-5. Molecular formula: C17H15F2IN4O4. Mole weight: 504.2266764. Catalog: ACM1035555635. | |
| TAK-733 | TAK-733 is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. MEK inhibitor TAK-733 selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types. Check for active clinical trials or closed clinical trials using this agent. Synonyms: TAK 733; TAK733. Grades: >98%. CAS No. 1035555-63-5. Molecular formula: C17H15F2IN4O4. Mole weight: 504.232. | |
| TAK-779 | TAK-779 is a potent, dual antagonist at chemokine receptors CCR2 and CCR5 with IC50=1.4 nM at CCR5 and 2.3 nM at CCR2. Antagonists of both CCR2 and CCR5 such as TAK-779 have been investigated for treatment of viruses, rheumatoid arthritis, multiple sclerosis, and cancer. CCR5 is particularly targeted for anti-HIV therapy, since HIV entry into cells requires chemokine coreceptors CCR5 and CXCR4. Synonyms: N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium chloride, TAK-799; TAK 779; TAK779; Takeda 779. Grades: >98%. CAS No. 229005-80-5. Molecular formula: C33H39ClN2O2. Mole weight: 531.13. | |
| Tak875 | Tak875. Alternative Names: TAK875;3-Benzofuranacetic acid, 6-[[2,6-diMethyl-4-[3-(Methylsulfonyl)propoxy][1,1-biphenyl]-3-yl]Methoxy]-2,3-dihydro-, (3S)-;(3S)-6-[[2,6-Dimethyl-4-[3-(methylsulfonyl)propoxy][1,1-biphenyl]-3-yl]methoxy]-2,3-dihydro-3-benzofuranacetic acid;TAK-875,TAK875;[(3S)-6-({2,6-Dimethyl-4-[3-(methylsulfonyl)propoxy]-3-biphenylyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid;(S)-2-(6-((2,6-Dimethyl-4-(3-(methylsulfonyl)propoxy)-[1,1-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid;TAK-875, >=98%;Fasiglifam. CAS No. 1000413-72-8. Molecular formula: C29H32O7S. Mole weight: 524.62518. Purity: 99%+. IUPACName: 2-[ (3S) -6-[[3-[2, 6-dimethyl-4- (3-methylsulfonylpropoxy) phenyl]phenyl]methoxy]-2, 3-dihydro-1-benzofuran-3-yl]aceticacid. Canonical SMILES: CC1=CC (=CC (=C1C2=CC (=CC=C2)COC3=CC4=C (C=C3)C (CO4)CC (=O)O)C)OCCCS (=O) (=O)C. Density: 1.252. Catalog: ACM1000413728. | |
| TAK-875 | TAK-875 is a potent, selective, and orally bioavailable GPR40 agonist, with a pharmacokinetic profile enabling long-acting drug efficacy. Synonyms: TAK875; TAK 875; Fasiglifam; 3-Benzofuranacetic acid, 6-[[2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2,3-dihydro-, (3S)-; (3S)-6-[[2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2,3-dihydro-3-benzofuranacetic acid; (+)-TAK 875; (3S)-6-([2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl]methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid. Grades: >98%. CAS No. 1000413-72-8. Molecular formula: C29H32O7S. Mole weight: 524.63. | |
| TAK-875 Hemihydrate | TAK-875 is a novel, orally available, selective GPR40 agonist. TAK-875 exhibits potent agonist activity and high binding affinity to the human GPR40 receptor with Ki of 38 nM. TAK-875 enhanced glucose-induced insulin secretion in a glucose-dependent manner in both human and rat islets. In rat insulinoma INS-1 833/15 cells, TAK-875 increased intracellular inositol monophosphate and calcium concentration, consistent with activation of the Gqα signaling pathway. In addition, TAK-875 (10 mg/kg, p.o.) significantly augmented plasma insulin levels and reduced fasting hyperglycemia in male Zucker diabetic fatty rats, whereas in fasted normal Sprague-Dawley rats, TAK-875 neither enhanced insulin secretion nor caused hypoglycemia even at 30 mg/kg. TAK-875 improves both postprandial and fasting hyperglycemia with a low risk of hypoglycemia and no evidence of β cell toxicity. TAK-875 significantly improved glycaemic control in patients with type 2 diabetes with minimum risk of hypoglycaemia. Synonyms: Fasiglifam hemihydrate; TAK875 hemihydrate; (3S)-6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy) biphenyl-3-yl)methoxy)-2,3-dihydro-l-benzofuran-3-yl)acetic acid hemihydrate. Grades: 98%. CAS No. 1374598-80-7. Molecular formula: C58H66O15S2. Mole weight: 1067.27. | |
| TAK-901 | TAK-901. Group: Biochemicals. Alternative Names: 5-[3-(Ethylsulfonyl)phenyl]-3,8-dimethyl-N-(1-methyl-4-piperidinyl)-9H-pyrido[2,3-b]indole-7-carboxamide. Grades: Highly Purified. CAS No. 934541-31-8. Pack Sizes: 1mg, 2mg, 5mg, 10mg, 25mg. Molecular Formula: C28H32N4O3S. US Biological Life Sciences. | Worldwide |
| TAK-901 | TAK-901 is a multi-targeted aurora inhibitor with IC50s of 21 and 15 nM for aurora A and B, respectively. Group: Inhibitors. CAS No. 934541-31-8. Molecular formula: C28H32N4O3S. Mole weight: 504.6458. Purity: 0.96. Catalog: ACM934541318. | |
| TAK-901 | TAK-901 is a small-molecule inhibitor of the serine-threonine kinase Aurora B with potential antineoplastic activity. Aurora B kinase inhibitor TAK-901 binds to and inhibits the activity of Aurora B, which may result in a decrease in the proliferation of tumor cells that overexpress Aurora B. Aurora B is a positive regulator of mitosis that functions in the attachment of the mitotic spindle to the centromere; the segregation of sister chromatids to each daughter cell; and the separation of daughter cells during cytokinesis. This serine/threonine kinase may be amplified and overexpressed by a variety of cancer cell types. Check for active clinical trials or closed clinical trials using this agent. Synonyms: TAK901, TAK-901, TAK 901. Grades: >98%. CAS No. 934541-31-8. Molecular formula: C28H32N4O3S. Mole weight: 504.64. | |
| TAK-960 | TAK-960 is an orally available PLK1 inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor TAK-960 selectively inhibits PLK1, inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells. PLK1 inhibition may result in the inhibition of proliferation in PLK1-overexpressed tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase crucial in the regulation of mitosis. Synonyms: TAK 960; TAK960. CAS No. 1137868-52-0. Molecular formula: C27H34F3N7O3. Mole weight: 561.61. | |
| TAK-960-d3 | TAK-960-d3. Group: Biochemicals. Alternative Names: 4-[(9-Cyclopentyl-7,7-difluoro-6,7,8,9-tetrahydro-5-methyl-6-oxo-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-N-(1-methyl-4-piperidinyl)benzamide-d3. Grades: Highly Purified. Pack Sizes: 1mg. Molecular Formula: CH31D3F3N7O3, Molecular Weight: 564.62. US Biological Life Sciences. | Worldwide |
| TAK-960 dihydrochloride | TAK-960 is an orally available, potent and selective PLK1 inhibitor that was in a phase I clinical trial in patients with advanced non-hematologic malignancies. Synonyms: 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-N-(1-methylpiperidin-4-yl)benzamide;dihydrochloride; TAK-960 (dihydrochloride); TAK 960 (dihydrochloride); TAK960 (dihydrochloride). Molecular formula: C27H36Cl2F3N7O3. Mole weight: 634.52. | |
